Stockscreener 앱 받기
6.88
9.73%
0.61
시간 외 거래:
7.05
0.17
+2.47%
전일 마감가:
$6.27
열려 있는:
$6.29
하루 거래량:
223.28K
Relative Volume:
0.29
시가총액:
$61.18M
수익:
-
순이익/손실:
$-7.82M
주가수익비율:
-6.0009
EPS:
-1.1465
순현금흐름:
$-8.00M
1주 성능:
+32.05%
1개월 성능:
-47.28%
6개월 성능:
+352.63%
1년 성능:
+242.29%
1일 변동 폭
$6.29
$7.36
1주일 범위
$5.05
$7.36
52주 변동 폭
$0.72
$20.32
에데사 바이오테크 Stock (EDSA) Company Profile
명칭
Edesa Biotech Inc
전화
(905) 475-1234
주소
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
6.88 | 52.82M | 0 | -7.82M | -8.00M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
에데사 바이오테크 주식(EDSA)의 최신 뉴스
Edesa Biotech Inc. Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Commercial R&D Costs PersistMargin Compression Risk - newsline.com
EDSA Q1 2026 Earnings: Misses EPS Estimates Amid Pre-Revenue Stage, Stock Rises 2.65%Mid-Term Outlook - newsline.com
Why Did EDSA Stock Rally More Than 70% Today? - Stocktwits
Edesa Biotech announces $3.5M PIPE financing - MSN
Edesa Biotech announces $3.5M private placement - TipRanks
Edesa Biotech Announces Insider-Led PIPE Financing Agreement - TipRanks
Edesa Biotech secures $3.5 million private placement financing - Investing.com
Edesa Biotech Raises $3.5 Million in Private Placement, Issues 729,241 Shares - TradingView
Edesa Biotech (Nasdaq: EDSA) sets $3.5M PIPE led by CEO - Stock Titan
CEO backs $3.5M raise to advance Edesa vitiligo work - Stock Titan
Edesa Biotech, Inc. announced that it expects to receive $3.42014 million in funding - marketscreener.com
Edesa Biotech Company Profile & Introduction - Moomoo
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech? - Stocktwits
Edesa reports exploratory data on AKI treatment candidate - Investing.com UK
Edesa reports exploratory data on AKI treatment candidate By Investing.com - Investing.com South Africa
Edesa Biotech Says Paridiprubart Linked to Lower Risk of Death in Acute Kidney Injury Patients - marketscreener.com
Exploratory AKI data show lower mortality with paridiprubart at Edesa (NASDAQ: EDSA) - Stock Titan
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury - GlobeNewswire
Acute Respiratory Distress Syndrome Market to Grow Steadily at a 3.8% CAGR Through 2036, Supported by Emerging ARDS Therapies | DelveInsight - GlobeNewswire Inc.
Edesa Biotech (NASDAQ: EDSA) CEO receives 1,671 restricted share units - Stock Titan
Edesa Biotech Shareholders Approve Directors and Compensation Plans - The Globe and Mail
Edesa Biotech (EDSA) director receives 19,000 restricted share units - Stock Titan
Edesa Biotech (EDSA) director granted 19,000 restricted share units - Stock Titan
Edesa Biotech (EDSA) director receives 19,000-share RSU award vesting over 12 months - Stock Titan
Edesa Biotech (EDSA) CFO receives 64,609 restricted share units under 2019 plan - Stock Titan
Edesa Biotech (EDSA) president awarded 64,609 restricted share units - Stock Titan
Edesa Biotech (EDSA) director receives 19,000-share equity grant, holds 30,000 - Stock Titan
[Form 4] Edesa Biotech, Inc. Insider Trading Activity - Stock Titan
Edesa Biotech (EDSA) director Da David Liu receives 19,000-share equity grant - Stock Titan
Edesa Biotech (NASDAQ: EDSA) boosts equity plan and reelects full board - Stock Titan
EDSA - Finviz
Edesa Biotech, Inc. (EDSA) Presents at Dermatology Drug Development Summit 2026Slideshow - Seeking Alpha
Edesa Biotech, Inc.Common Shares (NQ: EDSA - FinancialContent
EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial - Zacks Small Cap Research
Edesa Biotech Inc. (EDSA) Q1 2026 Earnings: Wider Than Expected Loss as Clinical Pipeline ProgressesTangible Book Value - Newser
EDSA Stock Price, Quote & Chart | EDESA BIOTECH INC (NASDAQ:EDSA) - ChartMill
Key facts: Edesa Biotech Q2 Loss $4.2M; to Present AKI Data - TradingView
Edesa Biotech, Inc. (EDSA) Presents at Respiratory Innovation Summit 2026Slideshow (NASDAQ:EDSA) 2026-05-19 - Seeking Alpha
EDSA stock soars more than 700% so far this year: Wall Street eyes further upside in run up to acute kidney injury data reveal - MSN
What's going on in today's session - ChartMill
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference - marketscreener.com
EDSA Should I Buy - Intellectia AI
Stonepine entities report 30,000-share stake in Edesa Biotech (EDSA) - Stock Titan
EDESA (EDSA) Schedule 13G/A amendment: Nantahala and principals report 0 shares - Stock Titan
Point72, Steven Cohen report 2 Edesa Biotech shares (NASDAQ: EDSA) - Stock Titan
Rubric Capital and Rosen Hold 7.74% of EDSA (NASDAQ: EDSA) - Stock Titan
Edesa Biotech to issue 90% of CEO’s salary as restricted share units - Investing.com UK
Edesa Biotech Boosts CEO Equity-Based Compensation Structure - TipRanks
에데사 바이오테크 (EDSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
에데사 바이오테크 주식 (EDSA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nijhawan Pardeep | Chief Executive Officer |
Mar 10 '26 |
Buy |
6.60 |
1,000 |
6,599 |
628,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 05 '26 |
Buy |
3.90 |
10,000 |
39,000 |
402,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 04 '26 |
Buy |
4.26 |
10,000 |
42,560 |
392,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 03 '26 |
Buy |
3.63 |
10,000 |
36,300 |
382,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.00 |
2,000 |
4,000 |
627,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.28 |
1,000 |
2,280 |
372,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 27 '26 |
Buy |
2.22 |
30,000 |
66,696 |
371,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 26 '26 |
Buy |
1.58 |
20,571 |
32,480 |
615,797 |
2.60%
0.94%
자본화:
|
볼륨(24시간):